- Financial records made public show the CEO of biotech company Moderna last year earned roughly $393 million from stock options he exercised and got a 50% raise.
CEO Stephane Bancel received $1.5 million in 2022, an increase of 50% from the previous year, and Moderna increased his target cash bonus, according to securities and exchange commission filing filed in March.
- The National Institutes of Health gave $1.7 billion in taxpayer funding to Moderna to develop the COVID vaccine, putting the CEO’s salary and stock options under scrutiny.
- After the Securities an Exchange Commission report was published, Bancel said he and his wife generated $393 million from the sale of stock options and they donated $176 million in after-tax proceeds to charity in 2022.
Share This Article: